肿瘤细胞治疗研究
MODALITY HUB
FOR TREATMENT
现在就能报名的（招募中）排在最前，共 3 项。同一状态内中国中心优先。信息来自 ClinicalTrials.gov 与 CDE 公开登记。能否入组、费用与可及性，以登记原文和主治医生判断为准。
FOR RESEARCH
A phase 1 trial of CD123-directed chimeric antigen receptor T-cell therapy in adults with relapsed/refractory acute myeloid leukemia or blastic plasma
CD123 靶向 CAR-T 细胞疗法在 r/r AML 和 BPDCN 患者中是可行的，并显示出良好的安全性特征，包括既往接受过 alloHCT 的患者。尽管估计的总体完全缓解率不高，但这些发现为进一步优化 CD123 CAR-T 细胞设计、患者选择和联合策略提供了基础。
The search for safe and effective CAR-T targets in AML.
Antibody format matters: A comparative analysis of VHH and scFv domains reveals superior in vivo CAR T cell function with VHH domains.
Exploring CAR cell therapies beyond CAR-T for myeloid malignancies.
Progress in reprogramming failed graft-versus-leukemia immunity in acute myeloid leukemia relapse after allogeneic transplantation.
Anti-CD123 CAR-T therapy combined with autologous SCT and venetoclax maintenance in refractory BPDCN ineligible for allogeneic transplantation: a case
Quantifying target antigen-dependent CAR T-cell performance against AML.
Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting.
Mechanical Properties Measured by Atomic Force Microscopy Help Evaluate Different Constructions of Re-engineered Chimeric Antigen Receptor-T Models.
Breakthroughs of CAR T-cell therapy in acute myeloid leukemia: updates from ASH 2024.
MEMBER ACCOUNT
登录成功会直接打开下一页。
